Zentek Ltd. (NASDAQ:ZTEK) Short Interest Update

Zentek Ltd. (NASDAQ:ZTEK) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 148,000 shares, a decline of 25.1% from the February 13th total of 197,500 shares. Based on an average daily volume of 45,800 shares, the days-to-cover ratio is currently 3.2 days. Currently, 0.2% of the shares of the stock are short sold.

Zentek Stock Down 0.2 %

NASDAQ ZTEK opened at $0.92 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.83 and a quick ratio of 1.48. The company’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $0.95. Zentek has a 12 month low of $0.50 and a 12 month high of $1.34. The company has a market capitalization of $95.76 million, a P/E ratio of -13.11 and a beta of 1.30.

Zentek (NASDAQ:ZTEK) last released its earnings results on Wednesday, February 12th. The company reported ($0.01) EPS for the quarter. Zentek had a negative return on equity of 58.13% and a negative net margin of 16,555.32%.

Institutional Investors Weigh In On Zentek

A number of large investors have recently made changes to their positions in ZTEK. Two Sigma Securities LLC acquired a new stake in shares of Zentek during the fourth quarter valued at approximately $31,000. Anson Funds Management LP acquired a new stake in shares of Zentek during the fourth quarter valued at approximately $145,000. Finally, Scotia Capital Inc. raised its holdings in shares of Zentek by 5.7% during the fourth quarter. Scotia Capital Inc. now owns 958,771 shares of the company’s stock valued at $867,000 after acquiring an additional 51,744 shares during the period. Institutional investors and hedge funds own 0.77% of the company’s stock.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.